方法：选取2012-01/2013-01来我院就诊的角膜异物患者102例188眼为研究对象，根据随机数字表法分为治疗组和对照组。两组患者均于裂隙灯下剔除角膜异物，术后治疗组患眼应用重组人表皮生长因子衍生物滴眼液联合妥布霉素进行治疗，对照组患眼仅应用妥布霉素治疗。比较两组治疗3d后的疗效。

结果：治疗后3d，治疗组的治愈率(93.7%)明显高于对照组治愈率(76.6%)，差异具有统计学意义(P<0.05)。治疗组荧光素染色阴性率为90.4%，高于对照组的46.8%，差异具有统计学意义(P<0.01)。

结论：rhEGF能够特异性和角膜上皮细胞受体结合，缩短损伤的角膜上皮的创伤愈合时间，加速愈合，是一种治疗外伤性角膜上皮缺损的有效方法。

METHODS: There were 102 patients with corneal foreign body(188 affected eyes)chosen for the study. All patients were divided into treatment group and control group according to the random number table. Both groups received corneal foreign body elimination by slit lamp. Postoperatively, the treatment group was given eye drops containing epidermal growth factor(JinYinShu)combined with tobramycin while the control group was only administrated with tobramycin. Treatment effects were compared 3d after treatment.

RESULTS: Three days after treatment, the cure rate in the treatment group(93.7%), was significantly higher than that in the control group(76.6%)(P<0.05). In the treatment group, fluorescein staining was negative in 90.4% of the cases, significantly higher than that in the control group(46.8%)(P<0.01).

CONCLUSION: The recombinant human epidermal growth factor is capable of integrating with corneal epithelial cells and endothelial cell receptor, shortening healing time of corneal epithelial wound, thus making it an effective treatment of traumatic corneal epithelial defect.